SCHEMBL3095427

SCHEMBL3095427

COC(=O)c1ccc2c(C3CCCCC3)c(-c3ccccc3C=O)n(CC(=O)OC(C)(C)C)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.38
MMP12 P39900 1/20 0.38
CNR2 P34972 1/20 0.38
CYP3A4 P08684 3/20 0.35
CYP2C19 P33261 3/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP2C9 P11712 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
CYP2D6 P10635 1/20 0.35
SCN9A Q15858 3/20 0.34
ATM Q13315 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
NR1I2 O75469 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4825604 0.89 PRKCA (0.38) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL772007 0.88 CNR2 (0.40) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL394368 0.87 CNR2 (0.39) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL923678 0.86 PRKCA (0.36) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL3091678 0.86 ALDH1A1 (0.35) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL4823883 0.86 CNR2 (0.38) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL3088640 0.86 PRKCA (0.40) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL3086384 0.86 SCN9A (0.36) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL3589949 0.85 PRKCA (0.40) PRKCAMMP12CNR2CYP3A4CYP2C19
SCHEMBL3599670 0.84 PRKCA (0.36) PRKCAMMP12CNR2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795247-B2 Tetracyclic indole derivatives as antiviral agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-09-14 US disclosed
EP-1807403-A2 TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2007-07-18 EP disclosed
US-20060100262-A1 Tetracyclic indole derivatives as antiviral agents ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) 2006-05-11 US disclosed
WO-2006046030-A2 TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100262-A1 Tetracyclic indole derivatives as antiviral agents IDO1, ZC3HAV1, IDO2 PRKCA 3874/4885MMP12 3319/4885CNR2 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.